Two small life sciences firms—Genevant and Arbutus—accused Moderna of violating their patents for the lipid nanoparticle technology used in Moderna's COVID-19 vaccine. Without this technology, Moderna ...

A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused ...

By adjusting the fat levels in mRNA-based drugs, researchers have found a way to bypass the liver and go straight to the ...

Creative Biolabs With the enabling platforms and technologies at its disposal, Creative Biolabs is poised to address critical challenges in ...

YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported positive results from ...

In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...

Using an approach called DNA origami, scientists at Caltech have developed a technique that could lead to cheaper, reusable ...